about
In touch with your feminine side: how oestrogen metabolism impacts prostate cancerThe Regulation of Steroid Action by Sulfation and DesulfationSteroid sulfatase inhibitors for estrogen- and androgen-dependent cancersStructure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agentsAnticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallographyChimeric microtubule disruptorsSTX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic miceA comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13 - 52) to modulate microvascular but not thermal hyperalgesia responses.In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer.C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression.Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX ExpressionIn vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol.The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers.The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.Recent developments of steroid sulfatase inhibitors as anti-cancer agents.The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy.Estrone Sulfate Transport and Steroid Sulfatase Activity in Colorectal Cancer: Implications for Hormone Replacement Therapy.Oestrogen and colorectal cancer: mechanisms and controversies.Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitorsDevelopment of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice.A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.Estrogen Activation by Steroid Sulfatase Increases Colorectal Cancer Proliferation via GPER.Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor.Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.1H NMR-MS-based heterocovariance as a drug discovery tool for fishing bioactive compounds out of a complex mixture of structural analogues
P50
Q26748579-439E19FC-F366-4E5F-9F0F-A2B604C82F68Q26799364-BC28653E-2622-4F75-8026-A57CEFF2F163Q26865148-0A3F0A73-1497-40A2-BB12-ED614603C90EQ27649821-97A4CA6E-DD3B-4AE2-A551-54CBB09C3633Q27651769-C79433BC-51F0-4DAC-ADD8-40287F0A814FQ27660515-CDC9AE6C-BC7C-43D2-8702-BDFCB39A0FF1Q28536340-19DAA279-6967-4DFE-AC0F-9F5AB9AE11B9Q30896011-1B7428D3-B3A2-4A66-9917-433CF4B61AFEQ33918055-61F7096F-014B-438D-974C-71C4648116ACQ34063537-51A9CA94-ACE9-4977-9081-BF895EFB4ABFQ36018283-1CCEF61E-6F69-4515-A62B-AC4E4F016FBAQ36134768-8D78E0C5-54D3-414C-8F04-56D54C2BFB03Q36610372-657B1BE4-EB22-449F-986C-7084FD5512CEQ36610771-E08D0DB3-8F04-4F97-A0B0-6CB0BEEC4D37Q36796680-D00FC14C-C377-475A-98FA-3A97BC082D14Q36964976-70A0AAB6-9219-4EB7-94F1-78BFA61E2C79Q37135243-B8E2D12C-DE97-4D41-B8F1-99A0347C2AC9Q37294022-C51B284D-4AF1-4617-98C2-1F7B883F3515Q37403634-EBF18F9C-C1F5-402F-829A-BF730B3683A5Q37683048-7F8B50AC-41BD-4DCC-BB70-4424E3CB476EQ38074097-193B7B39-868F-4F10-AA3A-AD94B7D6C436Q38773372-6B0012E5-CF39-407E-80BC-668CEA38E78CQ39940895-BC6BF683-652F-4E08-A23B-D96169D696EFQ39978053-02F4B7AE-5615-4F84-9B07-2A408110C546Q40020149-6E411B84-B347-4D1F-99BE-E8EBA5E520FDQ40027067-912E3902-F604-4F3E-A560-0EEBF30AA525Q43430946-11FF1175-A943-49F4-821D-39FD96563E96Q46281221-E2BA01E8-54D0-4E64-9C64-59D05F46D595Q46312571-5A6E1C75-1177-4362-8DA9-D207429068E7Q47628866-6673B7FC-C84C-4D08-8154-8C44F0132C46Q48206519-BF806620-9503-4FE0-9C28-2AB4AAC6EF7BQ51734282-25E94B85-051C-4F61-AD4E-B05F16A30319Q51784643-C5E321E2-0CC0-43D7-AEF9-C5CD06EF7840Q92322245-51774B28-DE3A-48E1-8CF8-D4FA549C10AF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paul Foster
@ast
Paul Foster
@en
Paul Foster
@es
Paul Foster
@nl
Paul Foster
@sl
Пол Фостер
@ru
type
label
Paul Foster
@ast
Paul Foster
@en
Paul Foster
@es
Paul Foster
@nl
Paul Foster
@sl
Пол Фостер
@ru
prefLabel
Paul Foster
@ast
Paul Foster
@en
Paul Foster
@es
Paul Foster
@nl
Paul Foster
@sl
Пол Фостер
@ru
P1053
D-1615-2011
P106
P21
P31
P3829
P496
0000-0001-7190-1592